This article describes the design and creation of I-O Optimise, a project that will collect real-world evidence about patients with lung cancer across many different countries. A specific structured approach was followed to select real-world data sources (RWDS) for inclusion in I-O Optimise and, as of October 31 2018, seven RWDS were included, providing information on more than 45,000 patients per year with lung cancer in Denmark, Norway, Portugal, Spain, Sweden and the UK. I-O Optimise is an ongoing project that has the potential to provide information that will be important in improving the care of patients with lung cancer.
Abstract Aims: To describe I-O Optimise, a multinational program providing real-world insights into lung cancer management.
Methods: Real-world data source (RWDS) selection for I-O Optimise followed a structured approach focused on population coverage, key variable capture, continuous/consistent data availability, record duration and data latency, and database expertise.
Results: As of October 31 2018, seven RWDS were included in I-O Optimise, providing data on characteristics, treatment patterns, and clinical outcomes from >45,000 patients/year with non-small cell lung cancer, small cell lung cancer, and mesothelioma across Denmark, Norway, Portugal, Spain, Sweden and the UK.
Conclusions: The ongoing I-O Optimise initiative has the potential to provide a broad, robust, and dynamic research platform to continually address numerous research objectives in the lung cancer arena.